Source comparison
ARA-290 Peptide: Comprehensive Comparison
Primary Mechanism CD131 innate repair receptor activation EPO-R homodimer activation (hematopoietic + tissue repair) Proposed FAK/VEGF pathway modulation ARA-290 offers tissue repair without hematocrit changes; EPO carries thrombotic risk Erythropoietic Effect
This comparison does not assign a generated winner or score.
- Primary Mechanism
- CD131 innate repair receptor activation
- EPO-R homodimer activation (hematopoietic + tissue repair)
- Proposed FAK/VEGF pathway modulation
- ARA-290 offers tissue repair without hematocrit changes; EPO carries thrombotic risk
- Erythropoietic Effect
- None (no impact on RBC, Hgb, or Hct)
- Significant (dose-dependent RBC production)
- None
- ARA-290 and BPC-157 avoid EPO's cardiovascular complications
- Clinical Trial Data
- Phase II trials in neuropathy (published)
- Extensive FDA-approved use in anemia
- No completed human trials
- ARA-290 has human safety/efficacy data; BPC-157 remains preclinical
- Anti-Inflammatory Action
- JAK2/STAT3, NF-κB suppression
- Indirect via hematopoietic pathways
- Proposed but mechanism unclear
- ARA-290 demonstrates quantified cytokine reduction in controlled trials
- Tissue Selectivity
- High (CD131 distribution determines effect)
- Broad (EPO-R expressed across many tissues)
- Unknown (proposed systemic distribution)
- ARA-290's receptor selectivity allows targeted application
- Storage Requirements
- −20°C lyophilized; −80°C reconstituted aliquots
- 2–8°C (stable as liquid formulation)
- −20°C lyophilized
- ARA-290 requires stricter cold chain than commercial EPO
- Synthesis Complexity
- Low (11 amino acids, SPPS-compatible)
- High (165 AA, requires mammalian expression)
- Moderate (15 amino acids)
- Shorter peptides like ARA-290 have lower synthesis cost but higher purity variance risk